US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class II · Moderate risk Ongoing

MGC Health

Reason This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.

Xiamen Kang Zhongyuan Biotechnology Co., Ltd. D-0462-2026
Class II · Moderate risk Ongoing

MGC Health

Reason This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.

Xiamen Kang Zhongyuan Biotechnology Co., Ltd. D-0461-2026
Class II · Moderate risk Ongoing

Discount Drug Mart Food Market

Reason This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.

Xiamen Kang Zhongyuan Biotechnology Co., Ltd. D-0460-2026
Class II · Moderate risk Ongoing

Discount Drug Mart Food Market

Reason This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.

Xiamen Kang Zhongyuan Biotechnology Co., Ltd. D-0459-2026
Class II · Moderate risk Ongoing

caring mill

Reason This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.

Xiamen Kang Zhongyuan Biotechnology Co., Ltd. D-0458-2026
Class II · Moderate risk Ongoing

exchange select

Reason This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.

Xiamen Kang Zhongyuan Biotechnology Co., Ltd. D-0457-2026
Class II · Moderate risk Ongoing

exchange select

Reason This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.

Xiamen Kang Zhongyuan Biotechnology Co., Ltd. NDC 83698-580-30 D-0456-2026
Class II · Moderate risk Ongoing

Vancomycin HCL

Reason Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Fagron Compounding Services NDC 71266-5082-01 D-0442-2026
Class II · Moderate risk Ongoing

Vancomycin HCI

Reason Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Fagron Compounding Services NDC 71266-5085-01 D-0441-2026
Class II · Moderate risk Ongoing

Vancomycin HCI

Reason Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Fagron Compounding Services NDC 71266-5083-01 D-0440-2026
Class II · Moderate risk Ongoing

norepinephrine Bitartrate

Reason Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Fagron Compounding Services NDC 71266-5027-02 D-0439-2026
Class II · Moderate risk Ongoing

norepinephrine Bitartrate

Reason Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Fagron Compounding Services NDC 71266-5026-02 D-0438-2026
Class II · Moderate risk Ongoing

Clonidine Transdermal System

Reason CGMP Deviations: use of an unapproved raw material

Teva Pharmaceuticals USA, Inc NDC 0591-3510-04 D-0474-2026
Class II · Moderate risk Ongoing

Clonidine Transdermal System

Reason CGMP Deviations: use of an unapproved raw material

Teva Pharmaceuticals USA, Inc NDC 0591-3509-04 D-0473-2026
Class II · Moderate risk Ongoing

Clonidine Transdermal System

Reason CGMP Deviations: use of an unapproved raw material

Teva Pharmaceuticals USA, Inc NDC 0591-3508-04 D-0472-2026
Class II · Moderate risk Ongoing

traMADol Hydrochloride Tablets

Reason Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stability (25¿C/60%RH).

Amneal Pharmaceuticals, LLC NDC 60219-2348-5 D-0408-2026
Class III · Low risk Terminated

Essential Calming Skin Gel

Reason Subpotent Drug

Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-05 D-0482-2026
Class III · Low risk Terminated

Skin Rehab

Reason Subpotent Drug

Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-04 D-0481-2026
Class III · Low risk Terminated

Remedy Gel

Reason Subpotent Drug

Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-12 D-0480-2026
Class I · High risk Ongoing

Magnesium Sulfate in Water for Injection

Reason Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.

Amneal Pharmaceuticals, LLC NDC 70121-1720-3 D-0478-2026
Class II · Moderate risk Ongoing

Xanax XR

Reason Failed Dissolution Specifications

Viatris, Inc. NDC 58151-506-91 D-0444-2026
Class II · Moderate risk Ongoing

Octreotide Acetate for Injectable Suspension

Reason Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Teva Pharmaceuticals USA, Inc NDC 0480-9262-08 D-0406-2026
Class II · Moderate risk Ongoing

Octreotide Acetate for Injectable Suspension

Reason Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Teva Pharmaceuticals USA, Inc NDC 0480-9259-08 D-0405-2026
Class II · Moderate risk Ongoing

Octreotide Acetate for Injectable Suspension

Reason Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Teva Pharmaceuticals USA, Inc NDC 0480-9257-08 D-0404-2026